Published Online : 2026-04-30
Introduction: An estimated 20 million new cancer cases were reported in 2025. The WHO predicts over 35 million new cancer cases by 2050, a 77% increase from 22 million cases in 2025. Chemotherapy has revolutionized cancer management by improving survival and offering hope for remission. Chemotherapy induced peripheral neuropathy (CIPN) is one of the most disabling and dose limiting complications, significantly affecting quality of life and treatment adherence. Aim: The study aims to study the effect of chemotherapy on nerve conduction
velocity with electrophysiological parameters. Objectives were to evaluate the nerve conduction velocity in patient receiving chemotherapy & to investigate motor and sensory peripheral nerve conduction abnormalities among patient receiving chemotherapy. Materials and Methods: The study was conducted on 80 subjects (40 Cases and 40 control). Result: Statistical comparison of nerve conduction velocity among different drug
classes showed significant differences, reaffirming that neurotoxicity is drugdependent, with platinum and axanes being most harmful. p-value: 0.003, Statistically significant difference in conduction velocity across
chemotherapy drugs. Conclusion: The significant drop in nerve conduction velocity confirms the effectiveness of electrophysiological testing in early detection and grading of neuropathy. Such objective tools should be employed routinely alongside clinical evaluation to monitor nerve function, guide treatment adjustments and initiate timely intervention.
Original Article
English
P. 7-12